Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
Find a Broker »
- li>
- li>
- li>
- li>
- li>
| Fiscal Q2 Ending 12/12 |
Fiscal Q1 Ending 09/12 |
Fiscal Q4 Ending 06/12 |
Fiscal Q3 Ending 03/12 |
Fiscal Q2 Ending 12/11 |
|
Sales/Revenue |
883,145 | 769,893 | 831,639 | 777,960 | 837,908 |
Cost of Goods Sold (COGS) incl. D&A |
574,365 | 486,216 | 511,901 | 499,811 | 544,120 |
COGS excluding D&A |
537,850 | 452,792 | 478,290 | 465,204 | 511,735 |
Depreciation & Amortization Expense |
36,515 | 33,424 | 33,611 | 34,607 | 32,385 |
Gross Income |
308,780 | 283,677 | 319,738 | 278,149 | 293,788 |
SG&A Expense |
143,308 | 128,696 | 131,261 | 126,122 | 134,207 |
Research & Development |
28,323 | 27,395 | 27,038 | 27,950 | 31,148 |
Other SG&A |
114,985 | 101,301 | 104,223 | 98,172 | 103,059 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
5,077 | -61 | 31,598 | 5,284 | 2,847 |
Non Operating Income/Expense |
-780 | 513 | 2,390 | 3,480 | 2,028 |
Equity in Affiliates (Pretax) |
NA | 0 | NA | 0 | 0 |
Interest Expense |
14,197 | 14,773 | 18,918 | 15,602 | 14,487 |
Gross Interest Expense |
14,197 | 14,773 | 18,918 | 15,602 | 14,487 |
Pretax Income |
145,418 | 140,782 | 144,340 | 134,621 | 144,275 |
Income Tax |
39,463 | 35,202 | 37,290 | 18,894 | 44,536 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
105,955 | 105,580 | 107,050 | 115,727 | 99,739 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
105,955 | 105,580 | 107,050 | 115,727 | 99,739 |
Extraordinaries & Discontinued Operations |
0 | 0 | 8,639 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 8,639 | 0 | 0 |
Net Income After Extraordinaries |
105,955 | 105,580 | 98,411 | 115,727 | 99,739 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
105,955 | 105,580 | 107,050 | 115,727 | 99,739 |
Operational EPS |
1.16 | 1.12 | 1.37 | 1.27 | 1.08 |
EPS (basic) |
1.13 | 1.13 | 1.24 | 1.24 | 1.07 |
EBITDA |
201,987 | 188,405 | 222,088 | 186,634 | 191,966 |
Depreciation & Amortization Expense |
36,515 | 33,424 | 33,611 | 34,607 | 32,385 |
Common Shares Outstanding |
94,450 | 94,335 | 94,296 | 94,124 | 94,043 |
Basic Shares Outstanding |
93,903 | 93,607 | 93,426 | 93,330 | 93,221 |
Diluted Shares Outstanding |
94,450 | 94,335 | 94,296 | 94,124 | 94,043 |
Diluted EPS after Extraordinary Items |
1.12 | 1.12 | 1.23 | 1.23 | 1.06 |
Discont. Operations Per Share |
0 | 0 | 0.09 | 0 | 0 |
Continued operations EPS |
1.13 | 1.13 | 1.15 | 1.24 | 1.07 |
*Figures in thousands of U.S. Dollars except shares outstanding.